Insider buying
5 insiders in a week, 2nd time since 2006Traded Nov 17 · filed 2 days later
Since the trade +0.5% · S&P 500 −2.3% · to Nov 19
Bought within 3% of the 52-week low, RSI 36, 37% under its 200-day average, 21 points behind the S&P 500 over 3 months
A Lineage Cell Therapeutics director paid $771K out of pocket for Lineage Cell Therapeutics shares. 4 other people at Lineage Cell Therapeutics bought some too, in the same month. It was the first purchase in 22 months.
Insider buying
5 insiders in a week, 2nd time since 2006Traded Nov 17 · filed 2 days later
Since the trade +0.5% · S&P 500 −2.3% · to Nov 19
Bought within 3% of the 52-week low, RSI 36, 37% under its 200-day average, 21 points behind the S&P 500 over 3 months
Insider buying
3 insiders in a week, 6th time since 2006Traded Nov 16 · filed 1 day later
Since the trade +3.1% · S&P 500 −3.3% · to Nov 19
Bought at the 52-week low, RSI 34, 38% under its 200-day average, 21 points behind the S&P 500 over 3 months
Insider buying
3 insiders in a week, 6th time since 2006Traded Nov 16 · filed 1 day later
Since the trade +3.1% · S&P 500 −3.3% · to Nov 19
Bought at the 52-week low, RSI 34, 38% under its 200-day average, 21 points behind the S&P 500 over 3 months
Insider buying
3 insiders in a week, 6th time since 2006Traded Nov 16 · filed the same day
Since the trade +3.1% · S&P 500 −3.3% · to Nov 19
Bought at the 52-week low, RSI 34, 38% under its 200-day average, 21 points behind the S&P 500 over 3 months
Insider buying
Traded Jan 27, 2025 · filed 2 days later
Since the trade +33.3% · S&P 500 +19.4% · to Nov 19
A Lineage Cell Therapeutics director paid $6M out of pocket for Lineage Cell Therapeutics shares. Shares held went up 19% with this purchase.
Insider buying
Traded Nov 26, 2024 · filed the same day
Since the trade +35.5% · S&P 500 +19.2% · to Nov 19
The CFO of Lineage Cell Therapeutics paid $8.8K out of pocket for Lineage Cell Therapeutics shares. 3 other people at Lineage Cell Therapeutics bought some too, in the same month. It was the first purchase in over a year.
Insider buying
Traded Nov 26, 2024 · filed the same day
Since the trade +35.5% · S&P 500 +19.2% · to Nov 19
Lineage Cell Therapeutics's General Counsel paid $9K out of pocket for Lineage Cell Therapeutics shares. 3 other people at Lineage Cell Therapeutics bought some too, in the same month. It was the first purchase in over a year.
Insider buying
Traded Nov 22, 2024 · filed 3 days later
Since the trade +62.7% · S&P 500 +20.2% · to Nov 19
A Lineage Cell Therapeutics director paid $23K out of pocket for Lineage Cell Therapeutics shares. 3 other people at Lineage Cell Therapeutics bought some too, in the same month. It was the first purchase in over a year.
Insider buying
Traded Nov 21, 2024 · filed 1 day later
Since the trade +36.7% · S&P 500 +20.6% · to Nov 19
The CEO of Lineage Cell Therapeutics paid $24K out of pocket for Lineage Cell Therapeutics shares. 3 other people at Lineage Cell Therapeutics bought some too, in the same month. It was the first purchase in over a year.